CEN Biotech Inc
CEN Biotech, Inc. focuses on the manufacture, production, and development of light emitting diode lighting technology and hemp-based products. It intends to cultivate hemp for usage in industrial, medical, and food products; and to provide digital marketing and web design related services. The company was incorporated in 2013 and is based in Windsor, Canada.
CEN Biotech Inc (CENBF) - Total Liabilities
Latest total liabilities as of September 2023: $10.61 Million USD
Based on the latest financial reports, CEN Biotech Inc (CENBF) has total liabilities worth $10.61 Million USD as of September 2023.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
CEN Biotech Inc - Total Liabilities Trend (2013–2022)
This chart illustrates how CEN Biotech Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
CEN Biotech Inc Competitors by Total Liabilities
The table below lists competitors of CEN Biotech Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Amigo Holdings PLC
LSE:AMGO
|
UK | GBX39.20 Million |
|
FOUR SEAS
BE:FS7
|
Germany | €1.68 Billion |
|
Lapidoth-Heletz Limited Partnership
TA:LPHL-L
|
Israel | ILA5.57 Million |
|
Works co uk PLC
LSE:WRKS
|
UK | GBX111.11 Million |
Liability Composition Analysis (2013–2022)
This chart breaks down CEN Biotech Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.05 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -4.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.31 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CEN Biotech Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CEN Biotech Inc (2013–2022)
The table below shows the annual total liabilities of CEN Biotech Inc from 2013 to 2022.
| Year | Total Liabilities | Change |
|---|---|---|
| 2022-12-31 | $10.15 Million | +0.51% |
| 2021-12-31 | $10.10 Million | -38.07% |
| 2020-12-31 | $16.31 Million | -50.33% |
| 2019-12-31 | $32.83 Million | +14.89% |
| 2018-12-31 | $28.58 Million | +1.93% |
| 2017-12-31 | $28.04 Million | +60.44% |
| 2016-12-31 | $17.47 Million | +23.90% |
| 2015-12-31 | $14.10 Million | +18.94% |
| 2014-12-31 | $11.86 Million | +4887.90% |
| 2013-12-31 | $237.72K | -- |